Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A severe combined immunodeficiency that results from defective IL7R expression causes T-B+NK+ SCID. Loss of IL-7R function leads to the loss of an antiapoptotic signal, resulting in a loss of T-cell selection in thymus.
Estimated prevalence: Unknown (Unknown prevalence).
1 clinical trial registered. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
27 publications have been identified in PubMed for T-B+ severe combined immunodeficiency due to IL-7Ralpha deficiency. Research spans Basic Science / Preclinical (63%), Gene Therapy / Novel Therapeutics (15%), and Review / Meta-Analysis (7%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 17 |
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 5:33 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about T-B+ severe combined immunodeficiency due to IL-7Ralpha deficiency
New treatment approaches | 4 | 15% |
Research summaries | 2 | 7% |
Patient case studies | 2 | 7% |
Other research | 1 | 4% |
Disease patterns and progression | 1 | 4% |
Gutiérrez-Zepeda BM (2026). [PMID: 42058195](https://pubmed.ncbi.nlm.nih.gov/42058195/). *Front Immunol*. [Case Report / Case Series]
Ward AC (2026). [PMID: 41750289](https://pubmed.ncbi.nlm.nih.gov/41750289/). *Biomolecules*. [Review / Meta-Analysis]
Cuéllar C (2026). [PMID: 41880474](https://pubmed.ncbi.nlm.nih.gov/41880474/). *Mem Inst Oswaldo Cruz*. [Basic Science / Preclinical]
Hirata M (2026). [PMID: 41252434](https://pubmed.ncbi.nlm.nih.gov/41252434/). *J Anim Sci*. [Gene Therapy / Novel Therapeutics]
Andreu-Ballester JC (2025). [PMID: 40182599](https://pubmed.ncbi.nlm.nih.gov/40182599/). *World J Gastroenterol*. [Basic Science / Preclinical]
Sadasivam M (2025). [PMID: 39912351](https://pubmed.ncbi.nlm.nih.gov/39912351/). *Immunol Invest*. [Basic Science / Preclinical]
González-Torbay A (2025). [PMID: 40170851](https://pubmed.ncbi.nlm.nih.gov/40170851/). *Front Immunol*. [Case Report / Case Series]
Jarjour NN (2025). [PMID: 40023156](https://pubmed.ncbi.nlm.nih.gov/40023156/). *Immunity*. [Basic Science / Preclinical]
Seissler J (2025). [PMID: 40855395](https://pubmed.ncbi.nlm.nih.gov/40855395/). *Transplantation*. [Basic Science / Preclinical]
Dong L (2025). [PMID: 40751765](https://pubmed.ncbi.nlm.nih.gov/40751765/). *J Clin Immunol*. [Basic Science / Preclinical]